Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | GGT1 | P19440 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839708 | 1.00 | CPB2 (0.48) | CPB2CPB1GGT1TBXAS1GAA | |
| SCHEMBL18845468 | 0.81 | PIN1 (0.46) | TBXAS1GAASMN1; SMN2 | |
| SCHEMBL4688926 | 0.79 | TBXAS1 (0.43) | TBXAS1GAASMN1; SMN2TERTTAAR1 | |
| SCHEMBL4688922 | 0.79 | TBXAS1 (0.43) | TBXAS1GAASMN1; SMN2TERTTAAR1 | |
| SCHEMBL3845409 | 0.77 | MEN1 (0.42) | GAA | |
| SCHEMBL15127687 | 0.74 | TBXAS1 (0.39) | TBXAS1GAASMN1; SMN2TAAR1 | |
| SCHEMBL24834446 | 0.73 | GRIA2 (0.51) | TBXAS1TAAR1FDPSFPR2GRIA1 | |
| SCHEMBL781663 | 0.73 | GRIA2 (0.51) | TBXAS1TAAR1FDPSFPR2GRIA1 | |
| SCHEMBL3838965 | 0.73 | GRIA2 (0.51) | TBXAS1TAAR1FDPSFPR2GRIA1 | |
| SCHEMBL30037960 | 0.73 | TBXAS1 (0.45) | TBXAS1TERTFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
| CN-1443173-A | Substituted imidazoles as TAFI a inhibitors | PFIZER LTD (US) | 2003-09-17 | — | — | CN | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | CPB2 234/4885CPB1 168/4885GGT1 1034/4885 |
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | CPB2 167/4885CPB1 181/4885GGT1 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.